Duquesne Family Office
VC Fund
Duquesne Family Office is a family investment office that is managed by Stanley Druckenmiller.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Duquesne Family Office invests in
Stages Duquesne Family Office invests in
Countries Duquesne Family Office invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Sue Meng
|
|||
Investment Focus
Industry
- Biotechnology 4 (22%)
- Medical 3 (17%)
- Health Care 3 (17%)
- Life Science 3 (17%)
- Therapeutics 3 (17%)
Stage
- Series B 5 (28%)
- Series C 3 (17%)
- Seed 2 (11%)
- Series A 2 (11%)
- Series D 1 (6%)
Country
- United States 13 (72%)
- Turkey 1 (6%)
- Saudi Arabia 1 (6%)
- United Kingdom 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Sue Meng
Partner, Managing Director and General Counsel
|
Partner, Managing Director and General Counsel | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ratio Therapeutics
|
Ratio Therapeutics develops radiotherapeutics for the treatment of cancers. They engaged in research and development platforms, trillium and macropa, enable the imaging, discovery, and advancement of radiopharmaceuticals. It enables doctors to detect a wide range of epithelial-derived cancers, such as breast, pancreatic, lung, colon cancers, andmore. | $70M / Series C / Jul 31, 2026 | |
Rivet Industries
|
Rivet Industries delivers front line hardware and software to the world's most important workers. | $57.5M / Series A / Mar 31, 2026 | |
Cellares
|
Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $257M / Series D / Jan 28, 2026 | |
Myome
|
Myome helps identify genes that cause disease and act based on leading science. The data is secure, portable, and reusable throughout life. | Venture - Series Unknown / Dec 11, 2025 | |
Curative
|
Curative provides employer-based health insurance plans and healthcare services. The company delivers a plan with no copays, no deductibles, and a fixed monthly premium, aiming to make medical care easier to access and manage. It offers preventive care including an annual baseline visit, behavioral health services, primary and specialty care,prescription drug coverage, and integration with a network of providers. Curative also supports virtual care through its telehealth offering, enabling members to consult clinicians remotely for common health issues. Previously, the company was involved in large-scale diagnostic testing and vaccine distribution during the COVID-19 pandemic, and has since shifted focus to its insurance and care management services. | $150M / Series B / Nov 28, 2025 | |
Guardian Metal Resources
|
Guardian Metal Resources is a mineral exploration and development company focused solely on the mining-friendly state of Nevada. | $18.3M / Post-IPO Secondary / Aug 19, 2025 | |
PureCycle Technologies
|
PureCycle Technologies offers the only recycled polypropylene with properties equal to virgin polymer. Its recycling service converts waste plastic into virgin-like plastic fully closing the loop on the reuse of recycled plastics while making recycled polypropylene more accessible at scale to companies desiring to use a sustainable, recycled resin.It was founded in 2015 and is headquartered in Ironton, Ohio. | $300M / Post-IPO Equity / Jun 17, 2025 | |
MetOx Technologies
|
MetOx is a commercial manufacturer of high-temperature superconducting (HTS) wire using YBCO. HTS wire transmits transmits vast amounts of electricity in small cross-sections without electrical loss and without generating heat. HTS wire is critical for upgrading transmission and distribution lines (T&D), enabling magnetic confinement fusionreactors, and building next generation MRI scanners. | $15M / Series B / Nov 19, 2024 | |
Lean Technologies
|
Lean Technologies is a FinTech startup that develops a platform to provide access to consumer financial data. The company's API suite, designed to abstract developers from the fragmentation of the financial infrastructure, enables businesses to seamlessly access their customers' financial data and initiate instant bank transfers. Thecompany aims to enhance the accessibility, transparency, and utility of financial data and payments for consumers and businesses, promoting a more inclusive and interconnected financial landscape. | $67.5M / Series B / Nov 11, 2024 | |
Precision Neuroscience
|
Precision Neuroscience is a neural platform for next-generation brain-computer interface technology. The company's goal is to provide breakthrough treatments for the one billion patients worldwide suffering from neurological illnesses. Its brain–computer interface is designed to be minimally invasive, safely removable, and capable ofprocessing large amounts of data.The company was founded in 2021 and is based in New York. | $102M / Series C / Nov 06, 2024 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Duquesne Family Office invest in?
Duquesne Family Office invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Duquesne Family Office?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Duquesne Family Office?
The team at Duquesne Family Office includes Sue Meng (Partner, Managing Director and General Counsel). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
